Lancet (London, England)HumansRenin-Angiotensin SystemIslet Amyloid PolypeptideDiabetes MellitusType 2
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Marcel H A Muskiet, Massimo Nardone, Patrick C N Rensen, David Z I Cherney, Mark E Cooper
Published: 202610.1016/S0140-6736(25)01776-3
Abstract
We hypothesise that amylin receptor agonists (eg, pramlintide) and dual amylin and calcitonin-receptor agonists (eg, cagrilintide), which are emerging treatments for obesity and type 2 diabetes, can activate the renin-angiotensin system (RAS) and pot…
Preview only. Read the full abstract at the source